Hepatocellular carcinoma (HCC) arises from a number of cirrhosis-related and non-cirrhosis-
related exposures and is one of the leading causes of cancer-related deaths worldwide …

Liver cancer is one of the most ordinary reasons for death among cancers. Hepatocellular
carcinoma (HCC) is the most common type of liver cancer. In spite of the fact that various …

The long-term survival benefit of treating unresectable hepatocellular carcinoma (HCC)
patients with transarterial chemoembolization (TACE) rather than conservative treatment …

Background This study aims to find out the possible optimal therapy and assess the
prognosis properly for patient with spontaneous rupture of hepatocellular carcinoma (HCC) …

Purpose: Sorafenib combined with transcatheter arterial chemoembolization (TACE) is one
of the common methods in the clinical treatment of advanced hepatocellular carcinoma …

Background Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by
the promotion of neoangiogenesis after transarterial chemoembolization (TACE). Objectives …

Hepatocellular carcinoma (HCC) has more recently become a leading cause of cancer‑
associated mortality worldwide. Particularly at an advanced stage, the prognosis is generally …

目的探讨细胞因子诱导的杀伤细胞(CIK) 免疫治疗联合肝动脉化疗栓塞(TACE)
术治疗原发性肝癌患者的临床疗效. 方法选择2012 年2 月~ 2014 年2 月间在本院确诊并行 …

The median number (range) of prior treatments was also significantly higher in the S-TACE
group than in the TACE-alone group in terms of both TACE (2 [1–3] vs. 1 [0–2], P\0.01) and …

摘要目的: 探讨中晚期肝细胞癌(HCC) 采用肝动脉化疗栓塞联合索拉菲尼治疗的临床疗效. 方法:
按照随机数字表法将2012 年3 月-2014 年3 月我院收治的中晚期HCC 患者分为两组 …